Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
This article was originally published in The Pink Sheet Daily
Executive Summary
With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.
You may also be interested in...
Cornerstone Buys EKR Therapeutics To Expand Hospital Growth Strategy
Cornerstone gains two commercial products for the acute-care hospital setting, Cardene and Retavase, with the acquisition of EKR Therapeutics for $125 million upfront and potential milestones.
With Innovative Purdue Deal, Infinity Finds Shelter From The Storm
In exchange for ex-U.S. rights to the bulk of its early-stage oncology pipeline, Infinity has secured a cash runway into 2013.
Discovery Finalizing Surfaxin “Complete Response,” Eyes 2008 Approval
Firm plans response to May 1 “approvable” letter that addresses biological activity test criteria, lipid-related impurities.